Nitric oxide and cardiovascular protection.
Nitric oxide (NO) plays a critical role in ischemic heart disease and ischemia-reperfusion. There is an increasing body of evidence to support the role of NO in myocardial and vascular protection in disease. The finding that NO might act as a trigger of late ischemic preconditioning (IPC) might lead to the development of novel anti-ischemic therapy. The role of NO signaling in the cardioprotective effects of ACE inhibitors and angiotensin II type 1 receptor(AT(1)) receptor antagonists is an active area of study.
Jugdutt
Bodh I
BI
Walter Mackenzie Health Sciences Center, Cardiology Division, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. bjugdutt@ualberta.ca
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000503:physiopathology* / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial; D009569:Nitric Oxide / Q000502:physiology* / Q000627:therapeutic use*; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin / Q000627:therapeutic use
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin; D009569:Nitric Oxide